BiomX (PHGE) Share-based Compensation (2019 - 2026)
BiomX (PHGE) posted Share-based Compensation of -$1.9 million for Q1 2026, down 386.87% sequentially from -$396000.0 in Q4 2025, and down 392.56% YoY from $659000.0 in Q1 2025.
BiomX (PHGE) Share-based Compensation (2019 - 2026) Analysis & Trends
BiomX has reported Share-based Compensation for 8 years, with the latest figure at -$1.9 million in Q1 2026.
- Quarterly Share-based Compensation fell 392.56% year-over-year to -$1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 million (down 198.02% YoY) and the FY2025 annual result came in at $2.1 million, down 41.67% from the prior year.
- Share-based Compensation retreated to -$1.9 million in Q1 2026 per PHGE's latest filing, from -$396000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $829000.0 in Q3 2024 and troughed at -$1.9 million in Q1 2026.
- A 5-year average of $163250.0 and a median of $317000.0 in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2025 and 2026: Share-based Compensation soared 803.9% in 2025, then sank 392.56% in 2026.
- Over 5 years, Share-based Compensation stood at $367000.0 in 2022, then gained by 13.9% to $418000.0 in 2023, then tumbled by 183.97% to -$351000.0 in 2024, then fell by 12.82% to -$396000.0 in 2025, then plunged by 386.87% to -$1.9 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered -$1.9 million, -$396000.0, and $438000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | - |
| 10 | BiomX | 359,064.97 | -808,935.03 | - | -1.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.93 Mn |
| Mar 31, 2026 | -1.93 Mn |
| Dec 31, 2025 | -396,000.00 |
| Dec 31, 2025 | -396,000.00 |
| Sep 30, 2025 | 438,000.00 |
| Sep 30, 2025 | 438,000.00 |
| Jun 30, 2025 | 696,000.00 |
| Jun 30, 2025 | 696,000.00 |
| Mar 31, 2025 | 659,000.00 |
| Mar 31, 2025 | 659,000.00 |
| Dec 31, 2024 | -351,000.00 |
| Dec 31, 2024 | -351,000.00 |
| Sep 30, 2024 | 829,000.00 |
| Sep 30, 2024 | 829,000.00 |
| Jun 30, 2024 | 77,000.00 |
| Jun 30, 2024 | 77,000.00 |
| Dec 31, 2023 | 418,000.00 |
| Dec 31, 2023 | 418,000.00 |
| Sep 30, 2023 | 195,000.00 |
| Sep 30, 2023 | 195,000.00 |